Pharmaceutical manufacturers are expanding sterile injectable capacity to resolve structural supply bottlenecks for GLP-1 class medications. Third-party contract development and manufacturing organizations (CDMOs) are acquiring existing facilities to expedite scale-up timelines.
Capacity Bottlenecks and Capex
The primary operational hurdle remains restricted availability of specialized auto-injector assembly lines and fill-finish capacity. Multi-billion-dollar investments announced by major pharmaceutical entities are projected to normalize inventory levels only by late 2025.